Loading organizations...

§ Private Profile · Redwood City, CA, USA
Mosanna Therapeutics is a technology company.
Mosanna Therapeutics is a clinical-stage biopharmaceutical company developing a novel pharmaceutical treatment for obstructive sleep apnea (OSA). Its lead candidate, MOS118, is a nighttime nasal spray designed to engage the body's natural control mechanisms for upper airway patency. It aims to provide a convenient, non-invasive pharmacological solution for OSA patients.
The full names and precise founding date of Mosanna Therapeutics' founders are not publicly detailed. The company emerged from the insight that an unmet medical need exists for an effective, non-mechanical pharmaceutical intervention for obstructive sleep apnea, aiming to restore physiological upper airway control.
Mosanna Therapeutics targets individuals diagnosed with obstructive sleep apnea seeking effective and user-friendly treatment options. Its vision is to enhance patient outcomes and quality of life by establishing a new pharmaceutical standard of care for OSA. The company aims to address high-unmet needs in sleep and respiratory disorders.
Mosanna Therapeutics has raised $80.0M across 1 funding round.
Mosanna Therapeutics has raised $80.0M in total across 1 funding round.
Mosanna Therapeutics has raised $80.0M in total across 1 funding round.
Mosanna Therapeutics's investors include Pivotal bioVenture Partners, Hewmun Lau, Dmitrij Hristodorov, Daniela Begolo, Tiba Aynechi, EQT Life Sciences, Sascha-Oliver Bucher, High-Tech Grunderfonds, Supermoon Capital.
I need to clarify an important correction: Mosanna Therapeutics is not a technology company—it is a biotech/pharmaceutical company, not a technology firm. This distinction is fundamental to understanding what the company actually does.
Mosanna Therapeutics is a clinical-stage biotech company pioneering a pharmaceutical approach to treating obstructive sleep apnea (OSA).[2] Founded in 2022, the company has developed MOS118, a nasal spray designed to restore the body's natural airway control during sleep, offering a drug-based alternative to traditional mechanical treatments like CPAP machines.[2][3]
The company serves millions of OSA patients worldwide who currently rely on uncomfortable mechanical devices.[6] Mosanna's core problem-solving approach is fundamentally different from existing treatments: rather than mechanically forcing the airway open, the nasal spray reactivates upper airway muscles to help restore the body's natural breathing reflex during sleep.[4][6] The company has raised more than $80 million from prominent life sciences investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, and Norwest, with offices in Redwood City, California and Basel, Switzerland.[2]
Mosanna was founded in 2022 and is backed by a veteran leadership team with deep pharmaceutical and biotech experience.[3] The company's leadership includes executives with decades of combined experience: a Chief Regulatory Officer with over 40 years in pharmaceuticals and 30+ years in regulatory affairs; a Chief Financial Officer with 15 years of experience launching and scaling venture-backed startups; and a Chief Executive Officer with over 30 years in biotech who previously served as President and CEO of Otonomy, where he guided a successful IPO and achieved FDA approval for multiple therapies.[3]
The company emerged from recognition that current OSA treatments—primarily mechanical interventions—are often uncomfortable and disruptive to sleep quality, creating significant unmet patient needs despite affecting millions worldwide.[6]
Mosanna represents a shift in sleep apnea treatment philosophy—from external mechanical intervention to pharmaceutical activation of natural biological processes.[3][6] This approach aligns with broader trends in precision medicine and patient-centric drug development, where improving quality of life and treatment adherence are increasingly central to therapeutic success.
The timing is significant: OSA affects millions globally and is associated with serious comorbidities including heart disease and hypertension.[6] Current mechanical treatments have high non-compliance rates due to discomfort and sleep disruption, creating a substantial market opportunity for an effective pharmaceutical alternative. Mosanna's approach could influence how the broader biotech industry thinks about treating sleep disorders and other conditions currently managed through mechanical or device-based solutions.
Mosanna is advancing MOS118 through Phase 2 clinical development, with the next critical milestone being demonstration of efficacy and safety in larger patient populations.[4] The company's success will depend on clinical trial results proving that pharmaceutical activation of airway reflexes can match or exceed the efficacy of mechanical treatments while improving patient compliance and quality of life.
If successful, Mosanna could establish a new standard of care for OSA treatment and potentially open doors for similar pharmaceutical approaches to other conditions currently managed through mechanical intervention. The company's experienced leadership and substantial funding position it well to navigate the regulatory pathway, though biotech development timelines remain inherently uncertain. The broader question shaping their journey: can a pharmaceutical solution truly replace decades of mechanical treatment paradigms in sleep medicine?
Mosanna Therapeutics has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $80M Series A | Pivotal BioVenture Partners, Hewmun LAU, Dmitrij Hristodorov, Daniela Begolo, Tiba Aynechi | EQT Life Sciences, Sascha Oliver Bucher, High Tech Grunderfonds, Supermoon Capital | Announced |